DBV Technologies | Stammkapital



Ordinary Share Capital Veränderung Datum
Acadia Pharmaceuticals USD 16K 0 2024-12
Alnylam Pharmaceuticals USD 1.29M 4K 2024-12
Amarin USD 305.2M 156K 2024-09
BioMarin Pharmaceutical USD 191K 0 2024-12
DBV Technologies USD 10.98M 1000 2024-09
Halozyme Therapeutics USD 123K 4K 2024-12
Incyte USD 193K 1000 2024-12
Insmed USD 1.79M 6K 2024-12
Ionis Pharmaceuticals USD 158K 0 2024-12
Neurocrine Biosciences USD 100K 0 2024-12
PTC Therapeutics USD 77K 1000 2024-12
Sarepta Therapeutics USD 10K 0 2024-12
Ultragenyx Pharmaceutical USD 92K 0 2024-12
United Therapeutics USD 800K 100K 2024-12



DBV Technologies Stammkapital - Diese Werte, historische Daten, Prognosen, Statistiken, Diagramme und ökonomische Kalender - Apr 2025.